Prokineticins are neuroprotective in models of cerebral ischemia and ischemic tolerance in vitro. (September 2016)
- Record Type:
- Journal Article
- Title:
- Prokineticins are neuroprotective in models of cerebral ischemia and ischemic tolerance in vitro. (September 2016)
- Main Title:
- Prokineticins are neuroprotective in models of cerebral ischemia and ischemic tolerance in vitro
- Authors:
- Landucci, Elisa
Lattanzi, Roberta
Gerace, Elisabetta
Scartabelli, Tania
Balboni, Gianfranco
Negri, Lucia
Pellegrini-Giampietro, Domenico E. - Abstract:
- Abstract: Bv8/prokineticin 2 (PK2) is a member of a bioactive family of peptides that regulate multiple functions in the CNS including hyperalgesia, neurogenesis, neuronal survival and inflammation. Recent studies have associated PK2 and prokineticin receptors (PKR) with human diseases, but because their role in neuropathology is still debated we examined whether prokineticins exert a protective or deleterious role in models of cerebral ischemia and ischemic tolerance in vitro . In order to mimic cerebral ischemia, we exposed primary murine cortical cell cultures or rat organotypic hippocampal slices to appropriate periods of oxygen-glucose deprivation (OGD), which leads to neuronal damage 24 h later. Ischemic tolerance was induced by exposing hippocampal slices to a preconditioning subtoxic pharmacological stimulus (3 μM NMDA for 1 h) 24 h before the exposure to OGD. Bv8 (10–100 nM) attenuated OGD injury in cortical cultures and hippocampal slices, and the effect was prevented by the PKR antagonist PC7. The development of OGD tolerance was associated with an increase in the expression of PK2, PKR1 and PKR2 mRNA and proteins and was prevented by addition of the antagonist PC7 into the medium during preconditioning. Both Bv8 at protective concentrations and the NMDA preconditioning stimulus promoted the phosphorylation of ERK1/2 and Akt. These findings indicate that the prokineticin system can be up-regulated by a defensive preconditioning subtoxic NMDA stimulus and that PK2Abstract: Bv8/prokineticin 2 (PK2) is a member of a bioactive family of peptides that regulate multiple functions in the CNS including hyperalgesia, neurogenesis, neuronal survival and inflammation. Recent studies have associated PK2 and prokineticin receptors (PKR) with human diseases, but because their role in neuropathology is still debated we examined whether prokineticins exert a protective or deleterious role in models of cerebral ischemia and ischemic tolerance in vitro . In order to mimic cerebral ischemia, we exposed primary murine cortical cell cultures or rat organotypic hippocampal slices to appropriate periods of oxygen-glucose deprivation (OGD), which leads to neuronal damage 24 h later. Ischemic tolerance was induced by exposing hippocampal slices to a preconditioning subtoxic pharmacological stimulus (3 μM NMDA for 1 h) 24 h before the exposure to OGD. Bv8 (10–100 nM) attenuated OGD injury in cortical cultures and hippocampal slices, and the effect was prevented by the PKR antagonist PC7. The development of OGD tolerance was associated with an increase in the expression of PK2, PKR1 and PKR2 mRNA and proteins and was prevented by addition of the antagonist PC7 into the medium during preconditioning. Both Bv8 at protective concentrations and the NMDA preconditioning stimulus promoted the phosphorylation of ERK1/2 and Akt. These findings indicate that the prokineticin system can be up-regulated by a defensive preconditioning subtoxic NMDA stimulus and that PK2 may act as an endogenous neuroprotective factor through the activation of the ERK1/2 and Akt transduction pathways. Graphical abstract: Highlights: Bv8/PK2 are protective in apoptotic and necrotic models of cerebral ischemia. Prokineticins are involved in the development of ischemic tolerance in vitro . Prokineticin neuroprotection is mediated by activation of ERK1/2 and Akt signaling. … (more)
- Is Part Of:
- Neuropharmacology. Volume 108(2016)
- Journal:
- Neuropharmacology
- Issue:
- Volume 108(2016)
- Issue Display:
- Volume 108, Issue 2016 (2016)
- Year:
- 2016
- Volume:
- 108
- Issue:
- 2016
- Issue Sort Value:
- 2016-0108-2016-0000
- Page Start:
- 39
- Page End:
- 48
- Publication Date:
- 2016-09
- Subjects:
- Bv8 -- Prokineticins -- Oxygen-glucose deprivation -- Preconditioning -- Ischemic tolerance -- Neuroprotection
PK2 prokineticin 2 -- PKR PK receptor -- PKR1 PK receptor 1 -- PKR2 PK receptor 2 -- PC7 (2-(5-(4-fluorobenzyl)-1-(4-methoxybenzyl)-1, 4, 5, 6-tetrahydro-4, 6-dioxo-1, 3, 5-triazin-2-ylamino)-ethyl)-guanidine) -- OGD oxygen-glucose deprivation -- NMDA N-methyl-d-aspartate -- PC preconditioning -- PI propidium iodide -- ERK extracellular-signal-regulated kinases -- Akt protein kinasi B -- GSk3β Glycogen synthase kinase 3 beta
Neuropsychopharmacology -- Periodicals
Autonomic Agents -- Periodicals
Neuropsychopharmacologie -- Périodiques
Neuropsychopharmacology
Periodicals
Electronic journals
615.78 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00283908 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.neuropharm.2016.04.043 ↗
- Languages:
- English
- ISSNs:
- 0028-3908
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.517500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 7452.xml